• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gene Therapy and Molecular Biology >Aptamers in oncology: a diagnostic perspective
【24h】

Aptamers in oncology: a diagnostic perspective

机译：肿瘤学适体：诊断学观点

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nucleic acid sequences can produce a wide variety of three-dimensional conformations. Some of these structural forms are able to interact with proteins and small molecules with high affinity and specificity. These sequences, comprising either double or single stranded oligonucleotides, are called “aptamers” based on the Greek word aptus, which means “to fit”. Using an efficient selection process, randomised oligonucleotide libraries can be rapidly screened for aptamers with the appropriate binding characteristics. This technology has spawned the development of a new class of oligonucleotide therapeutic products. However, while interest among pharmaceutical companies continues to grow with some candidates already in clinical trials and one in the market, there appears to be some reluctance to fully explore the diagnostic potential of this technology. This article will review aptamer developments in diagnostics, compare them with other oligonucleotide therapeutics and highlight both potentials and pitfalls of technological development in this area.
机译：核酸序列可以产生各种各样的三维构象。这些结构形式中的某些能够以高亲和力和特异性与蛋白质和小分子相互作用。这些包含双链或单链寡核苷酸的序列基于希腊词aptus（意为“适合”）被称为“适体”。使用有效的选择过程，可以快速筛选随机的寡核苷酸文库中具有适当结合特性的适体。这项技术催生了新型寡核苷酸治疗产品的开发。然而，尽管制药公司的兴趣在不断增长，一些候选药物已经在临床试验中，市场上已有一些候选药物，但似乎仍不愿充分探索该技术的诊断潜力。本文将回顾适体在诊断中的发展，将其与其他寡核苷酸治疗剂进行比较，并强调该领域技术发展的潜力和陷阱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号